• Sandoz delivers 100,000 packs of amoxicillin 250mg dispersible tablets (DT) to UN and joins UN Pneumonia Innovations Team
• Pneumonia is the leading cause of infectious death globally among children under five, killing 1 million children each year and amoxicillin is the #1 treatment for childhood pneumonia

Holzkirchen, October 23, 2014 – Sandoz today announces the delivery of 100,000 packs of amoxicillin 250mg dispersible tablets (DT) to the United Nations (UN). This follows Sandoz’ commitment to the UN Every Newborn Action Plan, launched in June …

October 15, 2014 – Today is International Day of Rural Women, established by the United Nations to bring awareness to the critical contribution rural women make to improving living conditions worldwide. For rural women, health issues such as pregnancy complications are significantly compounded by limited availability of knowledgeable medical staff. Two new global reports confirm the vital role midwives can play in dramatically reducing maternal and newborn death.

…

Holzkirchen, October 13, 2014 – Sandoz is pleased to announce that Generics Bulletin, a newsletter covering commercial and regulatory information for the global generics industry, has awarded the company with “Biosimilars Initiative of the Year”, for its file acceptance of G-CSF (filgrastim) in the US. Sandoz also achieved top-three podium positions in the Company of the Year; Company of the Year – Americas; and Innovation of the Year Awards categories.

On July 24, Sandoz, announced that the FDA accepted its application for filgrastim, making Sandoz the first company …

October 9, 2014 – Approximately 285 million people worldwide live with low vision and blindness, according to the World Health Organization. Of these, 39 million people are blind and 246 million have moderate or severe visual impairment. Often a result of poor living conditions, 90% of blind people live in low-income countries.

• Portuguese Health Authority grants marketing authorization for AirFluSal® Forspiro®
• Approval for 50-250 and 50-500µg dosage forms
• AirFluSal Forspiro already launched in four European countries and South Korea

Holzkirchen, October 09, 2014 – Sandoz announces today that the Portuguese Health Authority (Infarmed) has granted marketing authorization for AirFluSal® Forspiro®, an innovative new inhaler for patients with asthma and/or chronic obstructive pulmonary disease (COPD).

AirFluSal Forspiro has now been approved in a total of 10 …